You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Baseline characteristics grouped by 30-day patient mortality

From: Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment

  Overall (n = 80,330) 30-day mortality (n = 15,909) No 30-day mortality (n = 64,421) P-value*
Patient age (years), median (IQR) 78 (72–83) 79 (74–84) 77 (72–82) < 0.0001
Male, % 98.3 98.5 98.2 0.0100
Race, %
 White 81.1 77.3 82.0 < 0.0001
 Black 13.1 14.9 12.6 < 0.0001
 Other 5.8 7.8 5.3 < 0.0001
Hispanic ethnicity, % 7.0 7.9 6.8 < 0.0001
MRSA risk score variables, % (1 point, unless noted)
 Age >79 43.8 51.0 42.0 < 0.0001
 Hospitalization in the past 90 days (2 points) 27.8 40.7 24.7 < 0.0001
 Intensive care unit admission (2 points) 21.1 42.0 16.0 < 0.0001
 Outpatient IV antibiotic therapy in past 90 days 4.9 6.0 4.7 < 0.0001
 Nursing home resident in last 90 days 1.0 0.8 1.0 0.0292
 Cerebrovascular disease 18.1 20.0 17.7 < 0.0001
 Dementia 5.2 6.7 4.9 < 0.0001
 Female with diabetes mellitus 0.4 0.4 0.4 0.8881
MRSA risk score, median (IQR) 1 (0–3) 2 (1–2) 1 (0–2) < 0.0001
 Low (0–1), % 51.4 28.4 57.1 < 0.0001
 Medium (2–5), % 47.3 68.4 42.1 < 0.0001
 High (6–10), % 1.3 3.25 0.9 < 0.0001
Charlson comorbidity score, median (IQR) 2 (1–4) 3 (1–5) 2 (1–4) < 0.0001
Comorbid conditions, %
 Myocardial infarction 7.3 8.7 6.9 < 0.0001
 Heart failure 25.9 28.2 25.4 < 0.0001
 Chronic obstructive pulmonary disease 48.7 41.7 50.4 < 0.0001
 Liver disease 1.3 2.3 1.1 < 0.0001
 Renal disease 14.1 16.7 13.4 < 0.0001
 Diabetes 30.5 30.3 30.5 0.5493
 Neoplastic disease 25.2 31.1 23.8 < 0.0001
 HIV/AIDS 0.2 0.2 0.2 0.2145
Medication use within 90 days, %
 Cardiovascular medications 66.5 60.0 68.0 <0.0001
 Anti-diabetic medications 22.2 20.0 22.8 <0.0001
 Inhaled corticosteroids 21.1 14.8 22.7 <0.0001
 Systemic corticosteroidsa 22.2 21.1 22.5 0.0002
 Pulmonary medications 34.8 27.8 36.6 < 0.0001
Vasopressors, % 10.2 26.9 6.0 < 0.0001
Invasive mechanical ventilation, % 11.1 26.8 7.3 < 0.0001
Noninvasive mechanical ventilation, % 4.0 7.1 3.3 < 0.0001
Hemodialysis, % 18.3 23.5 17.0 < 0.0001
Organ failure, %
 Any organ failure, % 32.2 57.8 25.9 < 0.0001
  Respiratory 14.4 32.6 9.9 < 0.0001
  Cardiovascular 9.7 22.1 6.7 < 0.0001
  Neurological 2.5 4.2 2.0 < 0.0001
  Renal 20.1 35.3 16.3 < 0.0001
  Hematologic 4.1 8.3 3.0 < 0.0001
  Hepatic 0.7 2.0 0.3 < 0.0001
Antibiotic therapy, %
 MRSA therapy 36.4 42.9 34.8 < 0.0001
 Guideline-concordant CAP therapy 64.1 38.6 70.4 < 0.0001
 Pseudomonal therapy 17.5 23.8 15.9 < 0.0001
 Atypical therapy 75.2 54.3 80.4 < 0.0001
  1. MRSA Methicillin-resistant Staphylococcus aureus, IQR Interquartile range, IV Intravenous, HIV/AIDS Human immunodeficiency virus/acquired immunodeficiency syndrome, CAP Community-acquired pneumonia
  2. aIncludes oral and/or injectable corticosteroids
  3. *Comparison between “30-day mortality” versus “no 30-day mortality” groups